444 related articles for article (PubMed ID: 30306428)
1. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
2. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
3. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
[TBL] [Abstract][Full Text] [Related]
4. High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma.
Li X; Liu M; Zhang Z; Zhang L; Liang X; Sun L; Zhong D
Thorac Cancer; 2019 May; 10(5):1103-1110. PubMed ID: 30907518
[TBL] [Abstract][Full Text] [Related]
5. CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients.
Kimbung S; Inasu M; Stålhammar T; Nodin B; Elebro K; Tryggvadottir H; Ygland Rödström M; Jirström K; Isaksson K; Jernström H; Borgquist S
Breast Cancer Res; 2020 Nov; 22(1):123. PubMed ID: 33176848
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
7. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
8. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
9. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
10. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
Bartlett JM; Thomas J; Ross DT; Seitz RS; Ring BZ; Beck RA; Pedersen HC; Munro A; Kunkler IH; Campbell FM; Jack W; Kerr GR; Johnstone L; Cameron DA; Chetty U
Breast Cancer Res; 2010; 12(4):R47. PubMed ID: 20615243
[TBL] [Abstract][Full Text] [Related]
11. Genomic index of sensitivity to endocrine therapy for breast cancer.
Symmans WF; Hatzis C; Sotiriou C; Andre F; Peintinger F; Regitnig P; Daxenbichler G; Desmedt C; Domont J; Marth C; Delaloge S; Bauernhofer T; Valero V; Booser DJ; Hortobagyi GN; Pusztai L
J Clin Oncol; 2010 Sep; 28(27):4111-9. PubMed ID: 20697068
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Ma CX; Bose R; Ellis MJ
Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
[TBL] [Abstract][Full Text] [Related]
14. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
15. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.
Zheng M; Zhou Y; Yang X; Tang J; Wei D; Zhang Y; Jiang JL; Chen ZN; Zhu P
Breast Cancer Res Treat; 2014 Nov; 148(2):423-36. PubMed ID: 25348432
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.
Witzel I; Graeser M; Karn T; Schmidt M; Wirtz R; Schütze D; Rausch A; Jänicke F; Milde-Langosch K; Müller V
J Cancer Res Clin Oncol; 2013 May; 139(5):809-16. PubMed ID: 23392859
[TBL] [Abstract][Full Text] [Related]
17. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
19. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.
Khan SS; Karn T; Symmans WF; Rody A; Müller V; Holtrich U; Becker S; Pusztai L; Hatzis C
Breast Cancer Res Treat; 2015 Feb; 149(3):789-97. PubMed ID: 25651779
[TBL] [Abstract][Full Text] [Related]
20. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer.
Althobiti M; El-Sharawy KA; Joseph C; Aleskandarany M; Toss MS; Green AR; Rakha EA
Breast Cancer Res Treat; 2021 Oct; 189(3):621-630. PubMed ID: 34453638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]